Galderma announced that Mirvaso (brimonidine) 0.33% topical gel is now available for the treatment of persistent (nontransient) facial erythema of rosacea

Brimonidine is an alpha-2 adrenergic agonist that is believed to work by constricting the dilated facial blood vessels to reduce the redness of rosacea.

RELATED: Dermatological Disorders Resource Center

The approval in August 2013 was based on data collected from >550 patients enrolled in two Phase 3 clinical studies of 30 days. Results from both studies showed that adults who used Mirvaso demonstrated significantly greater improvement in the facial redness of rosacea than the vehicle gel.

Mirvaso is available as a 0.33% topical gel in 30g and 45g tubes.

For more information call (866) 735-4137 or visit